Shanghai Runda Medical Technology Co., Ltd. (SHA:603108)
China · Delayed Price · Currency is CNY 16.40
-0.26 (-1.56%)
Feb 4, 2026, 3:00 PM CST
SHA:603108 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 7,398 | 8,306 | 9,140 | 10,487 | 8,853 | 7,062 |
Other Revenue | 5.85 | 5.85 | 7.15 | 7.13 | 6.83 | 6.92 |
| 7,404 | 8,312 | 9,147 | 10,494 | 8,860 | 7,069 | |
Revenue Growth (YoY) | -12.21% | -9.13% | -12.84% | 18.45% | 25.34% | 0.24% |
Cost of Revenue | 5,753 | 6,211 | 6,731 | 7,564 | 6,468 | 5,158 |
Gross Profit | 1,651 | 2,101 | 2,416 | 2,931 | 2,392 | 1,911 |
Selling, General & Admin | 1,207 | 1,321 | 1,423 | 1,578 | 1,244 | 1,006 |
Research & Development | 117.43 | 116.16 | 147.14 | 146.22 | 122.71 | 87.1 |
Other Operating Expenses | 23.27 | 40.98 | 47.05 | 29.76 | 24.66 | 21.58 |
Operating Expenses | 1,413 | 1,545 | 1,702 | 1,952 | 1,443 | 1,175 |
Operating Income | 238.67 | 556.14 | 713.53 | 978.14 | 949.16 | 736.27 |
Interest Expense | -284.51 | -312.86 | -334.04 | -317.92 | -281.92 | -244 |
Interest & Investment Income | 91.58 | 123.19 | 254.94 | 145.28 | 142.18 | 150.68 |
Currency Exchange Gain (Loss) | -5.97 | -5.97 | 3.18 | -1.65 | -4.73 | 3 |
Other Non Operating Income (Expenses) | -23.45 | -22.43 | -12.15 | 6.8 | -27.55 | -31.57 |
EBT Excluding Unusual Items | 16.32 | 338.06 | 625.46 | 810.65 | 777.14 | 614.37 |
Impairment of Goodwill | -29.13 | -29.13 | -10.41 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -7.15 | -3.59 |
Gain (Loss) on Sale of Assets | 1.84 | 6.48 | 8.73 | 2.67 | -1.52 | 4.47 |
Asset Writedown | 3.62 | - | -11.07 | -34.71 | - | - |
Other Unusual Items | 30.12 | 30.12 | 42.85 | 41.05 | 11.99 | 20.58 |
Pretax Income | 22.77 | 345.54 | 655.56 | 819.65 | 780.46 | 635.84 |
Income Tax Expense | 101.62 | 156.08 | 212.92 | 164.54 | 182.26 | 132.01 |
Earnings From Continuing Operations | -78.85 | 189.46 | 442.64 | 655.11 | 598.2 | 503.83 |
Minority Interest in Earnings | -78.99 | -134.18 | -169.34 | -237.36 | -217.97 | -173.85 |
Net Income | -157.84 | 55.28 | 273.3 | 417.75 | 380.23 | 329.98 |
Net Income to Common | -157.84 | 55.28 | 273.3 | 417.75 | 380.23 | 329.98 |
Net Income Growth | - | -79.77% | -34.58% | 9.87% | 15.23% | 6.61% |
Shares Outstanding (Basic) | 593 | 614 | 581 | 580 | 576 | 579 |
Shares Outstanding (Diluted) | 593 | 614 | 581 | 597 | 594 | 579 |
Shares Change (YoY) | -4.34% | 5.63% | -2.56% | 0.45% | 2.63% | -0.87% |
EPS (Basic) | -0.27 | 0.09 | 0.47 | 0.72 | 0.66 | 0.57 |
EPS (Diluted) | -0.27 | 0.09 | 0.47 | 0.70 | 0.64 | 0.57 |
EPS Growth | - | -80.85% | -32.86% | 9.38% | 12.28% | 7.55% |
Free Cash Flow | 678.1 | 417.78 | 409.84 | -700.98 | 70.03 | -8.5 |
Free Cash Flow Per Share | 1.14 | 0.68 | 0.70 | -1.18 | 0.12 | -0.01 |
Dividend Per Share | 0.030 | 0.030 | 0.100 | 0.150 | - | 0.114 |
Dividend Growth | -70.00% | -70.00% | -33.33% | - | - | - |
Gross Margin | 22.30% | 25.28% | 26.41% | 27.93% | 27.00% | 27.03% |
Operating Margin | 3.22% | 6.69% | 7.80% | 9.32% | 10.71% | 10.42% |
Profit Margin | -2.13% | 0.66% | 2.99% | 3.98% | 4.29% | 4.67% |
Free Cash Flow Margin | 9.16% | 5.03% | 4.48% | -6.68% | 0.79% | -0.12% |
EBITDA | 554.88 | 872.9 | 1,031 | 1,286 | 1,240 | 1,039 |
EBITDA Margin | 7.49% | 10.50% | 11.27% | 12.25% | 14.00% | 14.70% |
D&A For EBITDA | 316.21 | 316.76 | 317.48 | 307.71 | 291.06 | 302.65 |
EBIT | 238.67 | 556.14 | 713.53 | 978.14 | 949.16 | 736.27 |
EBIT Margin | 3.22% | 6.69% | 7.80% | 9.32% | 10.71% | 10.42% |
Effective Tax Rate | 446.29% | 45.17% | 32.48% | 20.08% | 23.35% | 20.76% |
Revenue as Reported | 7,404 | 8,312 | 9,147 | 10,494 | 8,860 | 7,069 |
Advertising Expenses | - | 17.3 | 21.28 | 49.57 | 58.12 | 51.66 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.